Laura Masucci
Université de Montréal
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laura Masucci.
Neuro-oncology | 2013
Ameen Al-Omair; Laura Masucci; Laurence Masson-Côté; Mikki Campbell; Eshetu G. Atenafu; Amy Parent; D. Letourneau; Eugene Yu; Raja Rampersaud; Eric M. Massicotte; Stephen B. Lewis; Albert Yee; I. Thibault; Michael G. Fehlings; Arjun Sahgal
BACKGROUND Spine stereotactic body radiotherapy (SBRT) is increasingly being applied to the postoperative spine metastases patient. Our aim was to identify clinical and dosimetric predictors of local control (LC) and survival. METHODS Eighty patients treated between October 2008 and February 2012 with postoperative SBRT were identified from our prospective database and retrospectively reviewed. RESULTS The median follow-up was 8.3 months. Thirty-five patients (44%) were treated with 18-26 Gy in 1 or 2 fractions, and 45 patients (56%) with 18-40 Gy in 3-5 fractions. Twenty-one local failures (26%) were observed, and the 1-year LC and overall survival (OS) rates were 84% and 64%, respectively. The most common site of failure was within the epidural space (15/21, 71%). Multivariate proportional hazards analysis identified systemic therapy post-SBRT as the only significant predictor of OS (P = .02) and treatment with 18-26 Gy/1 or 2 fractions (P = .02) and a postoperative epidural disease grade of 0 or 1 (0, no epidural disease; 1, epidural disease that compresses dura only, P = .003) as significant predictors of LC. Subset analysis for only those patients (n = 48/80) with high-grade preoperative epidural disease (cord deformed) indicated significantly greater LC rates when surgically downgraded to 0/1 vs 2 (P = .0009). CONCLUSIONS Postoperative SBRT with high total doses ranging from 18 to 26 Gy delivered in 1-2 fractions predicted superior LC, as did postoperative epidural grade.
Cureus | 2017
David Tiberi; Laura Masucci; Daniel Shedid; Isabelle Roy; Toni Vu; Erica Patocskai; André Robidoux; Philip Wong
Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local treatment of primary stage I-III breast cancers. For patients with hormone-positive breast cancers receiving hormonal therapy, the risk of distant recurrence is under 20% and therefore, many patients may potentially be spared of chemotherapy. Consequently, several molecular signatures based on gene expression were developed to better determine which breast cancer patients would benefit from chemotherapy. We present the case of a 62-year-old woman diagnosed with an early stage hormone receptor-positive breast cancer that was treated with a partial mastectomy. Oncotype DX (Genomic Health, Redwood City, CA) molecular testing was performed on the surgical specimen, which reported a recurrence score of 0. The patient commenced adjuvant radiotherapy during which she developed symptoms suggestive of bone metastasis and was subsequently diagnosed with a spinal cord compression that required neurosurgery and radiotherapy. Pathology review of the specimen from the spine surgery revealed a metastatic breast carcinoma with neuroendocrine differentiation. Molecular assays such as Oncotype DX are increasingly used to prognosticate patient outcomes and help determine who may avoid chemotherapy. This case report seeks to illustrate that such assays should not be used in the presence of rare histological subtypes like neuroendocrine breast cancers, which are often under-reported. The current status of personalized medicine and gene assays in breast cancer is reviewed and potential strategies are suggested to identify these rare cases to better orient diagnostic and treatment decisions.
Neuro-oncology | 2018
Paul W. Sperduto; B.J. Deegan; Jing Li; K.R. Jethwa; Paul D. Brown; Natalie A. Lockney; Kathryn Beal; Nitesh Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Amir Zahra; John M. Buatti; James B. Yu; Veronica L. Chiang; Jason Molitoris; Laura Masucci; David Roberge; Diana D. Shi; Helen A. Shih; Adam C. Olson; John P. Kirkpatrick; Steve Braunstein; Penny K. Sneed; Minesh P. Mehta
Background Brain metastases are a common complication of renal cell carcinoma (RCC). Our group previously published the Renal Graded Prognostic Assessment (GPA) tool. In our prior RCC study (n = 286, 1985-2005), we found marked heterogeneity and variation in outcomes. In our recent update in a larger, more contemporary cohort, we identified additional significant prognostic factors. The purpose of this study is to update the original Renal-GPA based on the newly identified prognostic factors. Methods A multi-institutional retrospective institutional review board-approved database of 711 RCC patients with new brain metastases diagnosed from January 1, 2006 to December 31, 2015 was created. Clinical parameters and treatment were correlated with survival. A revised Renal GPA index was designed by weighting the most significant factors in proportion to their hazard ratios and assigning scores such that the patients with the best and worst prognoses would have a GPA of 4.0 and 0.0, respectively. Results The 4 most significant factors were Karnofsky performance status, number of brain metastases, extracranial metastases, and hemoglobin. The overall median survival was 12 months. Median survival for GPA groups 0-1.0, 1.5-2.0, 2.5-3, and 3.5-4.0 (% n = 25, 27, 30 and 17) was 4, 12, 17, and 35 months, respectively. Conclusion The updated Renal GPA is a user-friendly tool that will help clinicians and patients better understand prognosis, individualize clinical decision making and treatment selection, provide a means to compare retrospective literature, and provide more robust stratification of future clinical trials in this heterogeneous population. To simplify use of this tool in daily practice, a free online application is available at brainmetgpa.com.
Asian Spine Journal | 2018
Amer Sebaaly; Ahmed Najjar; Zhi Wang; Ghassan Boubez; Laura Masucci; Daniel Shedid
Study Design Retrospective case series. Purpose To evaluate the clinical and radiological efficacy of anterolateral kyphoplasty for cervical spinal metastasis. Overview of Literature Although the spine is the third most common site of tumor metastasis, the cervical spine is the least commonly affected (incidence, 10%–15%). Surgical decompression is highly challenging because of the proximity of neural and vascular elements. Kyphoplasty for cervical spine metastasis has been described in small case reports with promising results. Methods Retrospective analysis of a prospective collected single-center spine metastasis database was done for cervical kyphoplasty cases. Data pertaining to age, sex, primary tumor diagnosis, modified Tokuhashi score, Spinal Instability Neoplastic Score (SINS), preoperative Visual Analog Scale (VAS) score, and analgesic medication were extracted. Postoperative data included VAS score at postoperative day 1, duration of hospitalization, self-reported functional outcome, and VAS score at the last follow-up. Results Eleven patients (mean age, 62.5 years) with cervical spine metastases were treated with 15-level kyphoplasty. Mean Tokuhashi score was 8.1, and mean SINS was 7.85. Mean preoperative pain score was 7.1, and 82% of patients used opioid analgesics. Mean total bleeding volume was 100 mL. Mean complication-free length of stay was 2.6 days with a decrease in postoperative pain (VAS score=2.8, p <0.05). There was a 56% decrease in opioid dosage and the number of consumed analgesics (1.09, p =0.004). Eighty-two percent of the patients reported excellent improvement at the last follow-up self-assessment. Conclusions To our knowledge, this case series represents the largest series of vertebral augmentation using balloon kyphoplasty for cervical spinal metastasis. This technique is associated with low postoperative complications as well as significant decrease in pain, use of opioids, and length of hospital stay. The main indications for vertebral kyphoplasty are lytic lesions of the cervical spine, painful lesions refractory to medical treatment, SINS score of 6–10, and absence of posterior wall defect.
Journal of Medical Imaging and Radiation Oncology | 2017
D. Mathieu; Marie-Pierre Campeau; Stéphane Bedwani; David Roberge; Robert Doucet; Karim Zerouali; Houda Bahig; Toni Vu; Louise Lambert; Laura Masucci; Edith Filion
The purpose of this study is quantify intrafraction motion (IFM) during lung volumetric‐modulated arc therapy (VMAT) and evaluate the impact of mid‐treatment cone beam computed tomography (CBCT)‐guided patient repositioning on target coverage.
International Journal of Radiation Oncology Biology Physics | 2014
Z.S. Fawaz; D. Mathieu; Edith Filion; Louise Lambert; Laura Masucci
Materials and Methods: 258 SABR fractions were analyzed in total, including 774 translational vectors to evaluate intra-fraction displacement: 193 fractions from 50 patients with early stage non-small cell lung tumors and 65 fractions from 15 patients with vertebral metastatic tumors included in this retrospective study. All patients underwent SBRT at our center; treatment was delivered with RapidArc with a flattened 6-MV photon beam between April 2012 and June 2013. Precise reproducible patient positioning was routinely obtained with the stereotactic double-vacuum whole body immobilization system (BodyFIX, Medical Intelligence). The vertical, longitudinal and lateral vectors were obtained by using local rigid registration of the vertebra located at the level of the region of interest on pre/mid-treatment CBCT scans. Clinical data was obtained to assess the presence of a correlation with the displacement: age, gender, Karnofsky performance status, and pulmonary function test.
International Journal of Radiation Oncology Biology Physics | 2017
Paul W. Sperduto; Wen Jiang; Paul D. Brown; Steve Braunstein; Penny K. Sneed; Daniel A. Wattson; Helen A. Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A. Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William Sperduto; John P. Kirkpatrick; Norman Yeh; Laurie E. Gaspar; Jason K. Molitoris; Laura Masucci; David Roberge; James B. Yu; Veronica L. Chiang; Minesh P. Mehta
International Journal of Radiation Oncology Biology Physics | 2017
Paul W. Sperduto; Wen Jiang; Paul D. Brown; Steve Braunstein; Penny K. Sneed; Daniel A. Wattson; Helen A. Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A. Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William Sperduto; John P. Kirkpatrick; Norman Yeh; Laurie E. Gaspar; Jason K. Molitoris; Laura Masucci; David Roberge; James B. Yu; Veronica L. Chiang; Minesh P. Mehta
International Journal of Radiation Oncology Biology Physics | 2016
Houda Bahig; Dany Simard; Laurent Létourneau; Philip Wong; David Roberge; Edith Filion; David Donath; Arjun Sahgal; Laura Masucci
Cureus | 2017
Chennouf A; Arslanian E; David Roberge; Berthelet F; Bojanowski M; Bahary J; Laura Masucci; Belanger K; Florescu M; Wong P